| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_f7b6c0fa3946ffb7464221f39d22ce8e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_29c5d94f49a24f38a2b3585bfbc3b9d2
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_59102a77fb8977e898d15a38389d92f8
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_579c4846b7e52d3c82c658c7f0d6ccd9
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_cf59dd243dc4535fc8efd12e0a98a922
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_b6abb390787c981b75e66f1a7650df8c |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-565
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-56
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-21
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395 |
| filingDate |
2011-04-05^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2013-07-23^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3a50d7b1bed5daee693fb35a12aee05d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ac0527fc6653dc0c699ed0c1360151ee
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9c00d5c70dc557e32845336fd897dd9e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_69fdb489997cf20a770f220e7821c7e9
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c110b690ce6adc5456e2f361d2dca720 |
| publicationDate |
2013-07-23^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-8491903-B2 |
| titleOfInvention |
Method of treatment of neurodementing diseases using isolated, monoclonal, human, anti-B-amyloid antibody |
| abstract |
Isolated, monoclonal, human, anti-β-amyloid antibodies are provided which bind to dimeric forms of Ab with higher affinity than to monomeric forms of Ab and when bound to an Aβ polypeptide comprising Aβ(21-37) shield Aβ(21-37) from proteolytic digestion. The antibodies were shown to inhibit fibril formulation and reduce plaque size in vivo and to not bind brain vessel walls. Accordingly, the antibodies are useful in human and veterinary medicine for the treatment and prophylaxis of Alzheimer's disease and other neurodementing diseases. Methods of detecting or measuring the progression of a neurodementing disease also are provided. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10035823-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2022192636-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2022251048-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11286279-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11028129-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10428113-B2 |
| priorityDate |
2007-01-11^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |